Related Experiment Video
Updated: May 26, 2026

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
Published on: September 1, 2015
Congenital hepatic fibrosis and autosomal recessive polycystic kidney disease
Arvind Srinath1, Benjamin L Shneider
1Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA 15224, USA.
Insights
Congenital hepatic fibrosis (CHF) management in autosomal recessive polycystic kidney disease (ARPKD) requires awareness of portal hypertension and cholangitis. Hepatobiliary cancer is rare in childhood but increases with age.
Area of Science:
- Hepatology
- Pediatric Nephrology
- Genetics
Background:
- Congenital hepatic fibrosis (CHF) is a rare genetic disorder.
- Autosomal recessive polycystic kidney disease (ARPKD) often involves hepatic complications.
- Understanding CHF natural history is crucial for managing ARPKD patients.
Purpose of the Study:
- To review the natural history of CHF.
- To inform clinical decision-making for ARPKD patients.
- To identify key complications and outcomes in CHF.
Main Methods:
- Systematic literature search for CHF, ARPKD, Caroli disease, and related conditions.
- Data extraction on portal hypertension, infection, malignancy, mortality, and transplantation.
- Analysis of 1230 patients from 155 articles.
Main Results:
- Portal hypertension (409 patients) and cholangitis (152 patients) were common CHF sequelae.
- Hepatobiliary cancer (21 patients), primarily cholangiocarcinoma, occurred mainly in adults >40 years.
- Cholangitis was fatal in 3/23 children post-renal transplant.
Conclusions:
- ARPKD management must consider CHF-related issues like portal hypertension and cholangitis.
- Pediatric approaches to portal hypertension need adaptation for renal insufficiency.
- Cholangiocarcinoma is not a major childhood concern, but vigilance is needed in older adults.
Objectives:
The published natural history of congenital hepatic fibrosis (CHF) was examined to inform clinical decision making in autosomal recessive polycystic kidney disease (ARPKD).
Methods:
A systematic literature search of the data on CHF, ARPKD, Caroli disease, Caroli syndrome, and type V choledochal cyst was performed to extract data related to portal hypertension, infection, malignancy, mortality, and transplantation.
Results:
Information related to 1230 patients with CHF was extracted from 155 articles. Median and mean age at diagnosis were 2 and 11.2 years, respectively. Median and mean time followed after diagnosis were 5.0 and 7.5 years, respectively (range 0-38 years). Sequelae of portal hypertension (n = 409), cholangitis (n = 152), and malignancy (n = 21) were noted. The nature of the portal hypertension was similar to that in other pediatric conditions (164 with varices, 74 bleeding varices, 81 underwent portosystemic shunting). Documented cholangitis was fatal in 3 of 23 children who were infected after renal transplantation. Twenty-one patients developed hepatobiliary cancer, with the majority having cholangiocarcinoma (n = 19). Cholangiocarcinoma (CCA) was predominant in individuals older than 40 years with either Caroli syndrome or isolated CHF, not ARPKD (median and mean age at CCA diagnosis were 70.3 and 60.1 years, respectively; range 33-75 years). There was a relative paucity of data on combined liver-kidney transplantation.
Conclusions:
Clinical decision making in ARPKD should reflect an understanding of the potential issues emanating from CHF. Accepted pediatric specific approaches to portal hypertension are warranted but must take into consideration the stage of renal insufficiency and potential plans for renal transplantation. Cholangitis is a major issue and necessitates anticipatory guidance and awareness. CCA, although a dreaded complication, does not appear to be a major issue during childhood. The indications for liver and combined liver-kidney transplantation are controversial and warrant further analysis.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Inborn Errors of Metabolism
Cirrhosis II: Pathophysiology
Cirrhosis I: Introduction
Nephrons
Pedigree Analysis

